Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Preoperative NT-proBNP strongly predicts cardiovascular events after noncardiac surgery

08 Jan 2020

Preoperative N-terminal pro–B-type natriuretic peptide (NT-proBNP) is a robust predictor of vascular death and myocardial injury after noncardiac surgery (MINS) within 30 days after the procedure, reveals a study. Consequently, adding NT-proBNP thresholds to the Revised Cardiac Risk Index (RCRI) improves cardiac prediction.

Multivariable analyses revealed significantly increased risks of the composite of vascular death and MINS within 30 days of surgery with preoperative NT-proBNP values of 100 to <200 pg/mL (adjusted hazard ratios [aHR], 2.27, 95 percent confidence interval [CI], 1.90–2.70), 200 to <1,500 pg/mL (aHR, 3.63, 95 percent CI, 3.13–4.21) and 1,500 pg/mL (aHR, 5.82, 95 percent CI, 4.81–7.05) as compared to <100 pg/mL (reference group).

The corresponding incidences of this outcome were 12.3 percent (226 of 1,843), 20.8 percent (542 of 2,608) and 37.5 percent (223 of 595).

The addition of NT-proBNP thresholds to clinical stratification (ie, RCRI) also led to a net absolute reclassification improvement of 258 per 1,000 patients. Moreover, a statistically significant association was observed between preoperative NT-proBNP values and 30-day all-cause mortality (incidence: <100 pg/mL, 0.3 percent; 100 to <200 pg/mL, 0.7 percent; 200 to <1,500 pg/mL, 1.4 percent; 1,500 pg/mL, 4.0 percent).

This prospective cohort study was conducted in 16 hospitals across nine countries and included 10,402 patients aged 45 years who underwent inpatient noncardiac surgery. NT-proBNP levels in all patients were measured before surgery. Troponin T levels were also measured daily for up to 3 days postsurgery.

“External validation of the identified NT-proBNP thresholds in other cohorts would reinforce our findings,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.